Synthesis and in vivo evaluation of both (2R,3R)-[123I]- and (2S,3S)- -[123I]-trans-2-hydroxy-5-((E)-3-(iodo) allyloxy)-3-(4-phenyl-1-piperazinyl) tetralin as SPECT radiotracer

• Autorzy: Assaad T. , Al Rayyes A. H.
• Języki publikacji: EN

Abstrakty

EN

We report the synthesis of enantiopure benzovesamicol derivatives: (2R,3R)-[123I]-trans-2-hydroxy-5-((E)-3- -(iodo)allyloxy)-3-(4-phenyl-1-piperazinyl) tetralin and (2S,3S)-[123I]-trans-2-hydroxy-5-((E)-3-(iodo)allyloxy)-3-(4- phenyl-1-piperazinyl) tetralin; [(2R,3R)-[123I]-1 and (2S,3S)-[123I]-1]. Both compounds were obtained with radiochemical and optical purities greater than 97% and with radiochemical yields in the range of 50–60%. To determine whether these compounds could have potential advantage compared to [125I]-iodo benzovesamicol (IBVM), IBVM was also labelled and used as the reference compound in all in vivo experiments. Both (2R,3R)-[123I]-1 and (-)-[125I]-IBVM showed similar time activity curves (TACs) with the highest accumulations in the striatum region followed by the cortex, hippocampus and then cerebellum. While (2S,3S)-[123I]-1 showed an overall homogeneous brain distribution. However, time activity curves of (2R,3R)-[123I]-1 confirmed that this compound could be used to visualize the vesicular acetylcholine transporter (VAChT) in vivo, at each point of the kinetic study. Also (2R,3R)-[123I]-1 showed lower specific bindings compared to [125I]-IBVM. These results suggested that (2R,3R)-[123I]-1 is inferior in comparison with [125I]-IBVM for in vivo VAChT exploration.

Słowa kluczowe

EN

Alzheimer's disease; benzovisamicol derivatives; brain biodistribution; enantiomeric resolution; radioiodination; vesicular acetylcholine transporter (VAChT)

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2013
• Tom: Vol. 58, No. 2
• Strony: 261--267
• Opis fizyczny: Bibliogr. 20 poz., rys.

Twórcy

autor

Assaad T.

• Department of Chemistry, Atomic Energy Commission of Syria (AECS), P. O. Box 6091, Damascus, Syrian Arab Republic, Tel.: [phone], Fax: [phone]

autor

Al Rayyes A. H.

• Department of Chemistry, Atomic Energy Commission of Syria (AECS), P. O. Box 6091, Damascus, Syrian Arab Republic, Tel.: [phone], Fax: [phone]

Bibliografia

• 1. Altar CA, Marien MR (1988) [3H] Vesamicol binding in brain: autoradiographic distribution, pharmacology, and effects of cholinergic lesions. Synapse 2:486–493
• 2. Assaad T (2011) Synthesis and characterization of novel benzovesamicol analogs. Turk J Chem 35:189–200
• 3. Assaad T, Al Rayyes AH (2012) Radiosynthesis and biological evaluation of 123I-(±)-trans-2-hydroxy-5-((E)--3-(iodo)allyloxy)-3-(4-phenyl-1-piperazinyl) tetralin. Nukleonika 57;1:81–85
• 4. Assaad T, Mavel S, Emond P et al. (2007) Synthesis and ex vivo evaluation of aza-trozamicol analogs as SPECT radiotracers for exploration of the vesicular acetylcholine transporter. J Labelled Compd Radiopharm 50:139–145
• 5. Bahr BA, Clarkson ED, Rogers GA, Noremberg K, Parsons SM (1992) A kinetic and allosteric model for the acetylcholine transporter-vesamicol receptor in synaptic vesicles. Biochemistry 31:5752–5762
• 6. Bahr BA, Parsons SM (1986) Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker L-trans-2-(4-phenyl[3,4-3H]-piperidino) cyclohexanol. Proc Natl Acad Sci USA 83:2267–2270
• 7. Bando K, Naganuma T, Taguchi K et al. (2000) Piperazine analog of vesamicol: in vitro and in vivo characterization for vesicular acetylcholine transporter. Synapse 38:27–37
• 8. Emond P, Mavel S, Zea-Ponce Y et al. (2007) (E)-[125I]--5-AOIBV: a SPECT radioligand for thevesicular acetylcholine transporter. Nucl Med Biol 34:967–971
• 9. Jung YW, Frey KA, Mulholland GK et al. (1996) Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. J Med Chem 39:3331–3342
• 10. Jung YW, Van Dort ME, Gildersleeve DL, Wieland DM (1990) A radiotracer for mapping cholinergic neurons of the brain. J Med Chem 33:2065–2068
• 11. Kuhl DE, Minoshima S, Fessler JA et al. (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease and Parkinson’s disease. Ann Neurol 40:399–410
• 12. Mesulam MM, Mufson EJ, Levey AI, Wainer AI (1983) Cholinergic innervations of cortex by the basal forebrain: cytochemistry and cortial connection of septal area, diagonal band nuclei, nucleus basalis 9 substantia innominata) and hypothalamus in the rhesus monkey. J Comp Neurol 214:170–197
• 13. Mulholland GK, Jung YW (1992) Improved synthesis of [11C]methylamino-benzovesamicol. J Labelled Compd Radiopharm 31:253–259
• 14. Mulholland GK, Jung YW, Wieland DM, Kilbourn MR, Kuhl DE (1993) Synthesis of [18F]-fluoroethoxybenzovesamicol, a radiotracer for cholinergic neurons. J Labelled Compd Radiopharm 33:589–591
• 15. Parsons SM, Bahr BA, Rogers GA, Clarkson ED, Noremberg K, Hicks BW (1993) Acetylcholine transportervesamicol receptor pharmacology and structure. Prog Brain Res 98:175–181
• 16. Rogers GA, Parsons SM, Anderson DC et al. (1989) Synthesis, in vitro acetylcholine-storage-blockingactivities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino) cyclohexanol (vesamicol). J Med Chem 32:1217–1230
• 17. Sorger D, Schliebs R, Kampfer I et al. (2000) In vivo [125I]-iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immunolesion of rat basal forebrain cholinergic system. Nucl Med Biol 27:23–31
• 18. Van Dort ME, Jung YW, Gildersleeve DL, Hagen CA, Kuhl DE, Wieland DM (1993) Synthesis of the 123I- and 125I-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol. Nucl Med Biol 20:929–37
• 19. Whitehouse P, Price DL, Stribble RG et al. (1982) Alzheimer’s disease and senile dementia: loss of neurons in basal forebrain. Science 215:1237–1239
• 20. Zea-Ponce Y, Mavel S, Assaad T et al. (2005) Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorg Med Chem 13:745–753